Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Wednesday. The firm set a “buy” rating on the biotechnology company’s stock.

Separately, Barclays lowered their price objective on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th.

Cellectis Stock Performance

Cellectis stock opened at $1.54 on Wednesday. The firm has a 50 day simple moving average of $1.63 and a 200-day simple moving average of $1.91. The stock has a market cap of $85.59 million, a price-to-earnings ratio of -1.18 and a beta of 3.06. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. Cellectis has a 1-year low of $1.41 and a 1-year high of $3.38.

Institutional Investors Weigh In On Cellectis

A number of institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN lifted its stake in Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 12,500 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Cellectis in the 4th quarter valued at $962,000. Finally, B Group Inc. acquired a new position in Cellectis during the 4th quarter worth about $5,547,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.